MetaVia
Boston
About MetaVia
MetaVia is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Their Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP), and they have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain, and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, their lead Alzheimer’s drug, is in the IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s disease (inhibition of AChE, pTau, and amyloid-╬▓, and stimulation of NGF for nerve growth). An aging population has resulted in an increase in the prevalence of Alzheimer’s disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer’s disease, yet none of these four address disease modification.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $138.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:NRBO
- Website: metaviatx.com
- Phone: (857) 702-9600
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/metavia-10554 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.